Board of Directors Lipum

Fredrik Lehmann is a senior advisor at Flerie. He has held senior executive and operational roles at several biotech companies, including Oncopeptides (Head of Research and CMC), Recipharm (General Manager), and EpiEndo (CEO and CMC). He has also founded several life science companies, including OT Chemistry, which was acquired by Recipharm in 2015. Fredrik served as a venture partner at Industrifonden and Entrepreneur in Residence at Sound Bioventures. Fredrik has a Ph.D. from the University of Gothenburg and an Executive MBA from the Stockholm School of Economics.

Eva Johnsson, holds an M.D, Ph.D., and associate professorship from Gothenburg University. With 25 years of executive leadership experience in major pharmaceutical companies as well as the startup world, Eva has worked in clinical drug development and medical affairs, including regulatory approvals and drug commercialization, and has also engaged in business development and strategy and project management. She has held several senior roles with global clinical responsibility and has had positions in inflammation and pain as well as other therapeutic areas at Grünenthal, AstraZeneca, and BASF Pharma AG/Knoll Läkemedel AB.

Åsa Magnusson has a Bachelor of Business Administration and B2B Marketing from Lund University. She is a senior executive with long international commercial experience in the life science industry in both publicly listed and privately owned biotech and pharma companies. In her previous role as Chief Engagement & Commercial Officer (CCO) at Vicore Pharma and now through her own company Think Brand Direction, Åsa leverages her expertise and network within research-intensive organizations, to develop a clear go-to-market strategy essential for realizing the value of pipeline assets.

Åsa Hansdotter is an attorney-at-law and partner of the business law firm HWF Advokater AB in Helsingborg. She works with company and equity capital markets law, Swedish and international M&A and further handles corporate commercial matters as external legal counsel for listed and non-listed companies within the industry and life science sectors among others. During 2001-2017, Åsa was with Mannheimer Swartling, 2010-2017 as a partner. Åsa is a board member in i.a. Dizlin Pharmaceuticals AB, P Capital Partners AB and the Swedish Chamber of Commerce for Russia & CIS. Independent in relation to the company, the management and major shareholders.

Carl-Johan Spak is a senior advisor at Flerie Invest AB. Carl-Johan held senior positions at Recipharm between 2009 and April 2021, prior to which he was Head of Meda’s Nordic organisation and CEO of Recip AB. He is currently engaged as a board member in several life science companies, both in Sweden and internationally. Carl-Johan has a degree in dentistry and a PhD in cariology and pharmacology from Karolinska Institute. Among his board assignments are XSpray Pharma AB, Atrogi AB, EpiEndo ehf, Symcel Sverige AB and Buzzard Pharmaceuticals AB. Independent in relation to the company, company management and major shareholders.